Ixico Regulatory News (IXI)

19 June 2026

IXICO plc

("IXICO", the "Company" or the "Group")

Exercise of Options

IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that it has issued, conditional on admission, 926,686 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options ("Options") under the Company's October 2024 Option Awards (the "2024 Plan"). 926,686 of these Options were exercised by Bram Goorden, Chief Executive Officer and PDMR of the Company.

All tax and costs were paid separately by Mr Goorden with no sale of Ordinary Shares required. Following this exercise, Mr Goorden's holding has increased to 2,390,501 Ordinary Shares representing approximately 1.1% of the current Issued Share Capital of the Company.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 24 June 2026.

Total Voting Rights

Following Admission, the Company will have 218,974,282 Ordinary Shares in issue. This figure of 218,974,282 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.